Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD

1.4  -0.13 (-8.5%)

After market: 1.41 +0.01 (+0.71%)

Fundamental Rating

1

Overall GOSS gets a fundamental rating of 1 out of 10. We evaluated GOSS against 571 industry peers in the Biotechnology industry. GOSS has a bad profitability rating. Also its financial health evaluation is rather negative. GOSS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GOSS has reported negative net income.
In the past year GOSS has reported a negative cash flow from operations.
In the past 5 years GOSS always reported negative net income.
In the past 5 years GOSS always reported negative operating cash flow.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

GOSS has a better Return On Assets (-20.42%) than 77.62% of its industry peers.
With a Return On Equity value of -132.35%, GOSS is not doing good in the industry: 62.17% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -20.42%
ROE -132.35%
ROIC N/A
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GOSS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for GOSS has been increased compared to 1 year ago.
GOSS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GOSS has an improved debt to assets ratio.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

GOSS has an Altman-Z score of -3.58. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
GOSS has a Altman-Z score of -3.58. This is comparable to the rest of the industry: GOSS outperforms 44.41% of its industry peers.
A Debt/Equity ratio of 3.64 is on the high side and indicates that GOSS has dependencies on debt financing.
GOSS has a worse Debt to Equity ratio (3.64) than 84.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.64
Debt/FCF N/A
Altman-Z -3.58
ROIC/WACCN/A
WACCN/A
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.74 indicates that GOSS has no problem at all paying its short term obligations.
GOSS has a better Current ratio (6.74) than 65.90% of its industry peers.
A Quick Ratio of 6.74 indicates that GOSS has no problem at all paying its short term obligations.
GOSS has a better Quick ratio (6.74) than 66.07% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.92% over the past year.
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.44% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.27%
EPS Next 2Y21.6%
EPS Next 3Y18.29%
EPS Next 5Y15.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GOSS. In the last year negative earnings were reported.
Also next year GOSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as GOSS's earnings are expected to grow with 18.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.6%
EPS Next 3Y18.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (2/21/2025, 8:24:17 PM)

After market: 1.41 +0.01 (+0.71%)

1.4

-0.13 (-8.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-21 2025-03-21/amc
Inst Owners76.64%
Inst Owner Change-91.45%
Ins Owners0.69%
Ins Owner Change0%
Market Cap317.24M
Analysts82.67
Price Target7.76 (454.29%)
Short Float %2.65%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.66%
Min EPS beat(2)-5.81%
Max EPS beat(2)7.13%
EPS beat(4)3
Avg EPS beat(4)0.95%
Min EPS beat(4)-5.81%
Max EPS beat(4)7.13%
EPS beat(8)7
Avg EPS beat(8)5.49%
EPS beat(12)9
Avg EPS beat(12)3.75%
EPS beat(16)10
Avg EPS beat(16)1.92%
Revenue beat(2)1
Avg Revenue beat(2)1.46%
Min Revenue beat(2)-17.78%
Max Revenue beat(2)20.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.22%
EPS NQ rev (1m)-1.26%
EPS NQ rev (3m)-8.56%
EPS NY rev (1m)0%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.01
P/FCF N/A
P/OCF N/A
P/B 5.86
P/tB 5.86
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.46
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.42%
ROE -132.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 3.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -3.58
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)37.16%
Cap/Depr(5y)108.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y79.27%
EPS Next 2Y21.6%
EPS Next 3Y18.29%
EPS Next 5Y15.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.61%
EBIT Next 3Y20.68%
EBIT Next 5Y19.44%
FCF growth 1Y99.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.21%
OCF growth 3YN/A
OCF growth 5YN/A